Abstract
Aim:
WSS25 is a sulfated polysaccharide extracted from the rhizome of Gastrodia elata BI, which has been found to bind to bone morphogenetic protein 2 (BMP-2) in hepatocellular cancer cells. Since BMP-2 may regulate both osteoclasts and osteoblasts, here we investigated the effects of WSS25 on osteoclastogenesis in vitro and bone loss in ovariectomized mice.
Methods:
RAW264.7 cells or mouse bone marrow macrophages (BMMs) were treated with RANKL to induce osteoclastogenesis, which was assessed using TRAP staining, actin ring formation and pit formation assays, as well as bone resorption assay. Cell viability was detected with MTT assay. The mRNA levels of osteoclastogenesis-related genetic markers (TRAP, NFATc1, MMP-9 and cathepsin K) were detected using RT-PCR, while the protein levels of p-Smad1/5/8 and Id1 were measure with Western blotting. WSS25 was administered to ovariectomized mice (100 mg·kg−1·d−1, po) for 3 months. After the mice were euthanized, total bone mineral density and cortical bone density were measured.
Results:
In RAW264.7 cells and BMMs, WSS25 (2.5, 5, 10 μg/mL) did not affect the cell viability, but dose-dependently inhibited RANKL-induced osteoclastogenesis. Furthermore, WSS25 potently suppressed RANKL-induced expression of TRAP, NFATc1, MMP-9 and cathepsin K in RAW264.7 cells. Treatment of RAW264.7 cells with RANKL increased BMP-2 expression, Smad1/5/8 phosphorylation and Id1 expression, which triggered osteoclast differentiation, whereas co-treatment with WSS25 or the endogenous BMP-2 antagonist noggin suppressed the BMP-2/Smad/Id1 signaling pathway. In RAW264.7 cells, knockdown of Id1 attenuated RANKL-induced osteoclast differentiation, which was partially rescued by Id1 overexpression. In conformity to the in vitro experiments, chronic administration of WSS25 significantly reduced the bone loss in ovariectomized mice.
Conclusion:
WSS25 inhibits RANKL-induced osteoclast formation in RAW264.7 cells and BMMs by blocking the BMP-2/Smad/Id1 signaling pathway. WSS25 administration reduces bone loss in ovariectomized mice, suggesting that it may be a promising therapeutic agent for osteoporosis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, et al. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 2007; 80: 1311–8.
Wada T, Nakashima T, Hiroshi N, Penninger JM . RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17–25.
Boyle WJ, Simonet WS, Lacey DL . Osteoclast differentiation and activation. Nature 2003; 423: 337–42.
Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17: 1231–4.
Kikuta J, Ishii M . Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology 2013; 52: 226–34.
Baud'huin M, Lamoureux F, Duplomb L, Redini F, Heymann D . RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007; 64: 2334–50.
Teitelbaum SL . Bone resorption by osteoclasts. Science 2000; 289: 1504–8.
Ashley JW, McCoy EM, Clements DA, Shi Z, Chen T, Feng X . Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling. Assay Drug Dev Technol 2011; 9: 40–9.
Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F . Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand and osteoprotegerin biological activities. Exp Cell Res 2004; 293: 292–301.
Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, et al. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur J Pharmacol 2008; 588: 124–33.
Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889–901.
Teitelbaum SL, Ross FP . Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4: 638–49.
Okamoto M, Murai J, Yoshikawa H, Tsumaki N . Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 2006; 21: 1022–33.
Pham L, Beyer K, Jensen ED, Rodriguez JS, Davydova J, Yamamoto M, et al. Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation. J Cell Biochem 2011; 112: 793–803.
Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 2001; 142: 3656–62.
Lee J, Kim K, Kim JH, Jin HM, Choi HK, Lee SH, et al. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 2006; 107: 2686–93.
Yokota Y, Mori S . Role of Id family proteins in growth control. J Cell Physiol 2002; 190: 21–8.
Chan AS, Jensen KK, Skokos D, Doty S, Lederman HK, Kaplan RN, et al. Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PloS One 2009; 4: e7955.
Abe E . Function of BMPs and BMP antagonists in adult bone. Ann N Y Acad Sci 2006; 1068: 41–53.
Sotillo Rodriguez JE, Mansky KC, Jensen ED, Carlson AE, Schwarz T, Pham L, et al. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling. J Bone Miner Res 2009; 24: 1917–26.
Watts NB, Diab DL . Long-term use of bisphosphonates in osteoporosis. J Clin Endocr Metab 2010; 95: 1555–65.
Kennel KA, Drake MT . Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009; 84: 632–8.
Miyakoshi N . Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Design 2004; 10: 2615–27.
Pearce CL, Chung K, Pike MC, Wu AH . Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009; 115: 531–9.
Qiu H, Tang W, Tong XK, Ding K, Zuo JP . Structure elucidation and sulfated derivatives preparation of two alpha-D-glucans from Gastrodia elata Bl. and their anti-dengue virus bioactivities. Carbohyd Res 2007; 342: 2230–6.
Qiu H, Yang B, Pei ZC, Zhang Z, Ding K . WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)/Smad/Id1 signaling. J Biol Chem 2010; 285: 32638–46.
Chen X, Xiao F, Wang Y, Fang JP, Ding K . Structure-activity relationship study of WSS25 derivatives with anti-angiogenesis effects. Glycoconj J 2012; 29: 389–98.
Xiao F, Qiu H, Zhou L, Shen X, Yang L, Ding K . WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology 2013; 23: 524–35.
Ariyoshi W, Takahashi T, Kanno T, Ichimiya H, Shinmyouzu K, Takano H, et al. Heparin inhibits osteoclastic differentiation and function. J Cell Biochem 2008; 103: 1707–17.
Wei ZF, Tong B, Xia YF, Lu Q, Chou GX, Wang ZT, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-kappa B/c-Fos/NFATc1 pathways. PloS One 2013; 8 (3). e59171. doi: 10.1371/journal.pone.0059171.
Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H . Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol 2004; 92: 93–101.
Wilson SR, Peters C, Saftig P, Bromme D, Cathepsin K . Activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009; 284: 2584–92.
Negishi-Koga T, Takayanagi H . Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009; 231: 241–56.
Roggia C, Gao YH, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001; 98: 13960–5.
Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 2008; 105: 4289–94.
Xu J, Li ZX, Luo J, Yang F, Liu T, Liu MY, et al. Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption. J Med Chem 2012; 55: 3122–34.
Marie PJ . Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 2005; 16 Suppl 1: S7–10.
Edwards MW, Bain SD, Bailey MC, Lantry MM, Howard GA . 17 beta estradiol stimulation of endosteal bone formation in the ovariectomized mouse: an animal model for the evaluation of bone-targeted estrogens. Bone 1992; 13: 29–34.
Chen G, Deng C, Li YP . TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272–88.
Theill LE, Boyle WJ, Penninger JM . RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002; 20: 795–823.
Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH . Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Mol Pharmacol 2010; 77: 17–25.
Jensen ED, Pham L, Billington CJ Jr, Espe K, Carlson AE, Westendorf JJ, et al. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010; 109: 672–82.
Paul S, Lee JC, Yeh LC . A comparative study on BMP-induced osteoclastogenesis and osteoblastogenesis in primary cultures of adult rat bone marrow cells. Growth Factors 2009; 27: 121–31.
Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S, et al. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 2011; 26: 2511–22.
Onishi T, Ishidou Y, Nagamine T, Yone K, Imamura T, Kato M, et al. Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone 1998; 22: 605–12.
Miyazono K, Miyazawa K . Id: a target of BMP signaling. Sci STKE 2002; 2002: pe40.
Rice PJ, Adams EL, Ozment-Skelton T, Gonzalez AJ, Goldman MP, Lockhart BE, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 2005; 314: 1079–86.
Tomita M, Miwa M, Ouchi S, Oda T, Aketagawa J, Goto Y, et al. Nonlinear intestinal absorption of (1-->3)-beta-D-glucan caused by absorptive and secretory transporting system. Biol Pharm Bull 2009; 32: 1295–7.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (NSFC) (No 31230022), the National Science Fund for Distinguished Young Scholars (No 81125025), and the New Drug Creation and Manufacturing Program (No 2012ZX09301001-003).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chen, C., Qin, Y., Fang, Jp. et al. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling. Acta Pharmacol Sin 36, 1053–1064 (2015). https://doi.org/10.1038/aps.2015.65
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2015.65
Keywords
This article is cited by
-
Glycobiology in osteoclast differentiation and function
Bone Research (2023)
-
Sulfated Glucuronorhamnoxylan from Capsosiphon fulvescens Ameliorates Osteoporotic Bone Resorption via Inhibition of Osteoclastic Cell Differentiation and Function In Vitro and In Vivo
Marine Biotechnology (2022)
-
Strontium inhibits osteoclastogenesis by enhancing LRP6 and β-catenin-mediated OPG targeted by miR-181d-5p
Journal of Cell Communication and Signaling (2019)
